Jeffrey Wager, M.D.
Chairman & CEOjeff.firstname.lastname@example.org
Between 2011-2017, co-creator and BOD observer to Grupo Biotoscana SL, a Latin American specialty pharma roll-up financed by Advent International and Essex Woodlands Healthcare Ventures focused on cancer, infectious and rare diseases, leading to its USD 1 billion 2017 IPO on sales of ~$240M and 600 staff in 10 LatAm markets.
From 2006 – 2010, formed and led Artisan Pharma, Inc. as its founding CEO, raising $53M, building the entire team and implementing a 750 patient, 17 country Phase 2b/3 study ultimately leading to Artisan’s acquisition by Asahi Kasei Pharma Corporation (Japan) in 2011.
In 2000, formed Apeiron Partners, a FINRA-registered life sciences investment bank focused on corporate spin-outs, M+A, corporate venture capital and principal investments. In the process, successfully completed six spin-outs, including Targacept, Inc. (NASD:TRGT), Artisan Pharma (from Asahi Kasei), Biocritica ($120M annual revenue Xigris® franchise from Eli Lilly) and KBI BioPharma (from KBI). Between 2003 and 2006, advised on the establishment and investment of Z-Cube s.r.l., the €60M corporate venture fund of the Zambon Group, a €700M privately-held Italian pharmaceutical company.
Between 1995-2000, Dr. Wager was with Medical Science Partners, a Harvard-sponsored VC fund focused on forming spin-outs from the Harvard medical system, including deCODE, ICAgen, Inspire, Oravax (subsequently Acambis), ZYCOS, Inc. and Diatide, amongst others.
Dr. Wager began his career with a life sciences unit of the Bank of Tokyo, where he led business development, responsible for helping Japanese pharmaceutical clients establish overseas affiliates, design and implement overseas clinical development and structure strategic alliances.
Dr. Wager is also a co-founder and Chairman of Proterris, Inc., a P2/3 clinical-stage firm focused on therapeutic uses of low-dose gaseous and small molecule carbon monoxide for transplant, fibrosis, and oncology indications.
Dr. Wager earned his MD from Rush Medical College and his MBA from the University of Chicago.
Jeffrey Wager, M.D.
Chairman & CEO
Chief Business OfficerMike.Garrett(at)EnBiotix-dot-com
Mr. Garrett is responsible for formulation and execution of corporate and strategic development at EnBiotix, in addition to managing the legal group. He has more than 25 years experience in the life sciences industry working in business development, investment management, licensing and intellectual property positions for large companies, venture funds and entrepreneurial biopharma groups.
From 2006 to 2014 Mr. Garrett was Vice President of Corporate and Strategic Development at Scynexis, Inc., most recently as a member of the team that executed the company’s $62M IPO. From 2004 to 2006, Mr. Garrett was a Managing Director of Pharmavent Partners, a European Life Sciences venture capital fund headquartered in Paris, where he was responsible for UK-based investment opportunities. From 2001 to 2004, he was Global Vice President, Ventures and Business Development for BTG plc, a FTSE-250 company with responsibility for the company’s portfolio of 15 investments in early stage to public companies. Prior to this Mr. Garrett worked in the corporate venture group of Aventis (Paris) and in their business development group. Earlier in his career he was a patent attorney in the Rhone-Poulenc Intellectual Property department, based in France and the UK.
Mr. Garrett is a British and European Patent Attorney, holds an Honors degree in Chemistry from Southampton University, UK and an Executive Certificate in General Management from the Cedep-INSEAD business school, France.
Chief Business Officer
Diane Joseph-McCarthy, Ph.D.
Senior Vice President, Discovery & Early Developmentdiane.j-m(at)enbiotix-dot-com
Diane Joseph-McCarthy is Senior Vice President, Discovery and Early Development at EnBiotix, with more than 20 years drug discovery and leadership experience in the pharmaceutical and biotechnology sector. Before joining EnBiotix, she was an Associate Director in the Infection iMED at AstraZeneca, where she led an innovative group of scientists as well as a global team in Predictive Science. Dr. Joseph-McCarthy was also part of several task forces aimed at transforming Infection’s early portfolio. Prior to that she was at Wyeth where she held positions of increasing responsibility. She has been actively involved in the discovery of several compounds that have reached clinical trials. Dr. Joseph-McCarthy received her PhD from MIT and was a postdoctoral fellow at Harvard University and Harvard Medical School. She has more than 70 publications/patents and has given numerous invited talks. She also has served as a member of the National Academy of Sciences Polio Antiviral Advisory Committee as well as editorial advisory boards for international journals.
Diane Joseph-McCarthy, Ph.D.
Senior Vice President, Discovery & Early Development
Benjamin Perrone, Ph.D.
Director, Business Development & Financeben.perrone(at)enbiotix-dot-com
Benjamin Perrone has over ten years of biomedical research, development, and translation experience. Before joining EnBiotix, he worked as Senior Associate, New Ventures in the Boston University Office of Technology Development, where he helped spin out six NewCos built around Boston University technologies in the life sciences, med tech, and healthcare I.T. spaces, and built a new application and evaluation process for the Ignition gap funding award program, with templates later incorporated by the BU Coulter Foundation Award and by the NSF SBIR program.
He is also a Program Leader at the Boston chapter of the Startup Leadership Program, an angel-sponsored training program for outstanding startup founders and innovators, and splits his free time between kite-surfing and bridge. He received his Ph.D. in Biomedical Engineering from Boston University, and a B.A. with Honors in Physics from the University of Chicago.